Siligmueller & Norvid Wealth Advisors LLC Purchases Shares of 164,711 Perspective Therapeutics, Inc. $CATX

Siligmueller & Norvid Wealth Advisors LLC acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 164,711 shares of the company’s stock, valued at approximately $565,000.

Several other large investors have also recently modified their holdings of CATX. Ground Swell Capital LLC purchased a new stake in Perspective Therapeutics during the 2nd quarter valued at about $56,000. Los Angeles Capital Management LLC bought a new stake in Perspective Therapeutics in the second quarter valued at approximately $61,000. Geode Capital Management LLC boosted its stake in shares of Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after purchasing an additional 188,887 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Perspective Therapeutics by 118.4% during the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after purchasing an additional 405,612 shares during the period. Finally, Walleye Capital LLC grew its holdings in shares of Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock worth $645,000 after purchasing an additional 148,013 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CATX. UBS Group reiterated a “buy” rating and set a $7.00 price target (down from $18.00) on shares of Perspective Therapeutics in a report on Friday, November 21st. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, November 11th. Finally, B. Riley Financial reduced their price target on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Four equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $11.50.

Perspective Therapeutics Price Performance

CATX stock opened at $5.65 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.66. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $6.16. The firm has a 50-day moving average of $3.42 and a 200 day moving average of $3.23.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.